Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Exosome Diagnostics And DxS Diagnostic Innovations Collaborate To Develop Blood-Based Tests For Key Cancer Mutations
Exosome Diagnostics, Inc. ("ExosomeDX") and DxS Ltd. ("DxS") announced that they will collaborate on the development of blood-based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS" industry leading Scorpions(R) real-time PCR Mutation Test Kits in conjunction with ExosomeDX"s xOS(TM) technology which harvests high-quality nucleic acids from blood exosomes.
generic viagra online
Biomedical Sciences Companies Expanding In Asia Invested More Than US$500 Million In Singapore
Global biomedical sciences companies invested more than US$500 million in
News of the day
Safety And Cognitive Stability Are Key Findings In Phase IIA Trial Of New Alzheimer's Disease Treatment From Humanetics Corporation
The results of a preliminary clinical trial suggest that a new Alzheimer"s drug from Humanetics Corporation is safe for daily use and that cognitive performance in patients with mild to moderate disease remained stable during the six-week course of the trial. The lack of decline in cognitive performance was an encouraging finding to be further evaluated in a Phase IIB clinical trial.
Mental Health

Glenmark's Novel Molecule For Diabetes, Melogliptin To Enter Phase III Trials

In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), "Melogliptin", Glenmark"s investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight. In this 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose (p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009